Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 33 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2017 Filed Jun 7, 2017 16:34 UTC |
Zelenkofske StevenChief Medical Officer
|
GrantOrdinary Shares | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038308 · doc4.xml · nonDerivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Read SEC document |
| May 09, 2017 Filed May 10, 2017 13:59 UTC |
Kapusta Matthew CDirector · CEO, CFO, Managing Director
|
GrantRestricted Stock Unit · Derivative | 175,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-019229 · doc1.xml · derivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Ordinary Shares · 175,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest 50% on March 14, 2018 and 50% on March 14, 2019, if the Reporting Person continues to be employed by the Issuer or a subsidiary of the Issuer employing the Reporting Person through and including said dates. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| May 09, 2017 Filed May 10, 2017 13:59 UTC |
Kapusta Matthew CDirector · CEO, CFO, Managing Director
|
GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001140361-17-019229 · doc1.xml · derivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Ordinary Shares · 175,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The Stock Option vests 25% on March 14, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 21, 2017 Filed Jun 8, 2017 16:33 UTC |
Petry HaraldChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,422 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-038555 · doc4.xml · derivative · entry 3 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,230 Underlying: Ordinary Shares · 25,422 shares Expires 2022-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Stock Option was exercised at a price of 3.07 Euros per share. The conversion from Euro to U.S. dollars ($) applied the exchange rate of 1.0737 Euros to U.S. dollars as of the exercise date (the "Exchange Rate"). F4 · derivative.exercise_date: The Stock Option vested in full on February 6, 2014. Read SEC document |
| March 21, 2017 Filed Jun 8, 2017 16:33 UTC |
Petry HaraldChief Scientific Officer
|
SaleOrdinary Shares | 25,422 | $6.03 | $153,289.58 |
DisclosureSEC source: 0001209191-17-038555 · doc4.xml · nonDerivative · entry 2 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2017. F3 · price: The shares were sold at a price of 5.6159 Euros per share. The conversion from Euro to U.S. dollars applied the Exchange Rate. Read SEC document |
| March 21, 2017 Filed Jun 8, 2017 16:33 UTC |
Petry HaraldChief Scientific Officer
|
Exercise / conversionOrdinary Shares | 25,422 | $3.30 | $83,798.54 |
DisclosureSEC source: 0001209191-17-038555 · doc4.xml · nonDerivative · entry 1 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Stock Option was exercised at a price of 3.07 Euros per share. The conversion from Euro to U.S. dollars ($) applied the exchange rate of 1.0737 Euros to U.S. dollars as of the exercise date (the "Exchange Rate"). Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:26 UTC |
Garen JonathanChief Business Officer
|
GrantPerformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003723 · doc1.xml · derivative · entry 2 Garen Jonathan · CIK 0001693817 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:26 UTC |
Garen JonathanChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003723 · doc1.xml · derivative · entry 1 Garen Jonathan · CIK 0001693817 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:02 UTC |
SCHAFFER DAVIDDirector
|
GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003702 · doc1.xml · derivative · entry 2 SCHAFFER DAVID · CIK 0001692929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:02 UTC |
SCHAFFER DAVIDDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003702 · doc1.xml · derivative · entry 1 SCHAFFER DAVID · CIK 0001692929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:20 UTC |
Meyer ChristianChief Medical Officer
|
GrantPreformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003712 · doc1.xml · derivative · entry 2 Meyer Christian · CIK 0001693826 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:20 UTC |
Meyer ChristianChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003712 · doc1.xml · derivative · entry 1 Meyer Christian · CIK 0001693826 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:22 UTC |
Petry HaraldChief Scientific Officer
|
GrantPerformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003715 · doc1.xml · derivative · entry 2 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:22 UTC |
Petry HaraldChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003715 · doc1.xml · derivative · entry 1 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:28 UTC |
Keson-Brookes MaikenGeneral Counsel
|
GrantPerformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003727 · doc1.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:28 UTC |
Keson-Brookes MaikenGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003727 · doc1.xml · derivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:03 UTC |
Soteropoulos PaulaDirector
|
GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003704 · doc1.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:03 UTC |
Soteropoulos PaulaDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003704 · doc1.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:00 UTC |
Lewis WilliamDirector
|
GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003699 · doc1.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:00 UTC |
Lewis WilliamDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003699 · doc1.xml · derivative · entry 1 Lewis William · CIK 0001402051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 19:56 UTC |
Astley-Sparke PhilipDirector
|
GrantRestricted Stock Units · Derivative | 25,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003695 · doc1.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 25,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 19:56 UTC |
Astley-Sparke PhilipDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003695 · doc1.xml · derivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 19:57 UTC |
Kaye JackDirector
|
GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003697 · doc1.xml · derivative · entry 2 Kaye Jack · CIK 0001376099 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 19:57 UTC |
Kaye JackDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003697 · doc1.xml · derivative · entry 1 Kaye Jack · CIK 0001376099 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:19 UTC |
Kapusta Matthew CDirector · CEO, CFO, Managing Director
|
GrantPerformance Share Units · Derivative | 162,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003709 · doc1.xml · derivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,124 Underlying: Ordinary Shares · 162,500 shares Expires not disclosed F1 · derivative.exercise_date: Performance Shares Units of a maximum of 162,500 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F2 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:25 UTC |
Cantor Maria ESVP, Investor Relations · SVP, Investor Communications
|
GrantPreformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003720 · doc1.xml · derivative · entry 2 Cantor Maria E · CIK 0001542768 · SVP, Investor Relations · SVP, Investor Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:25 UTC |
Cantor Maria ESVP, Investor Relations · SVP, Investor Communications
|
GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003720 · doc1.xml · derivative · entry 1 Cantor Maria E · CIK 0001542768 · SVP, Investor Relations · SVP, Investor Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:17 UTC |
van Deventer SanderDirector
|
GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003707 · doc1.xml · derivative · entry 2 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Managing Partner Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. F4 · ownership.nature: Under Mr. van Deventer's employment agreement with Forbion Capital Partners, he is required to transfer the Restricted Stock Units and stock options to Forbion Capital Partners. As a managing partner of Forbion Capital Partners, Mr. van Deventer has a partial beneficial interest in the Restricted Stock Units and stock options transferred to Forbion Capital Partners. Mr. van Deventer disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:17 UTC |
van Deventer SanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003707 · doc1.xml · derivative · entry 1 van Deventer Sander · CIK 0001543084 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Managing Partner Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. F4 · ownership.nature: Under Mr. van Deventer's employment agreement with Forbion Capital Partners, he is required to transfer the Restricted Stock Units and stock options to Forbion Capital Partners. As a managing partner of Forbion Capital Partners, Mr. van Deventer has a partial beneficial interest in the Restricted Stock Units and stock options transferred to Forbion Capital Partners. Mr. van Deventer disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:23 UTC |
Firuta Paul EChief Commercial Officer
|
GrantPreformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003717 · doc1.xml · derivative · entry 2 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:23 UTC |
Firuta Paul EChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003717 · doc1.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:05 UTC Amendment |
Garen JonathanChief Business Officer
|
GrantPerformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008378 · doc1.xml · derivative · entry 2 Garen Jonathan · CIK 0001693817 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:05 UTC Amendment |
Garen JonathanChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008378 · doc1.xml · derivative · entry 1 Garen Jonathan · CIK 0001693817 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:07 UTC Amendment |
Meyer ChristianChief Medical Officer
|
GrantPreformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008384 · doc1.xml · derivative · entry 2 Meyer Christian · CIK 0001693826 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:07 UTC Amendment |
Meyer ChristianChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008384 · doc1.xml · derivative · entry 1 Meyer Christian · CIK 0001693826 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:08 UTC Amendment |
Petry HaraldChief Scientific Officer
|
GrantPerformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008385 · doc1.xml · derivative · entry 2 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:08 UTC Amendment |
Petry HaraldChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008385 · doc1.xml · derivative · entry 1 Petry Harald · CIK 0001693830 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:06 UTC Amendment |
Keson-Brookes MaikenGeneral Counsel
|
GrantPerformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008381 · doc1.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:06 UTC Amendment |
Keson-Brookes MaikenGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008381 · doc1.xml · derivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:03 UTC Amendment |
Cantor Maria ESVP, Investor Relations · SVP, Investor Communications
|
GrantPreformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008374 · doc1.xml · derivative · entry 2 Cantor Maria E · CIK 0001542768 · SVP, Investor Relations · SVP, Investor Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:03 UTC Amendment |
Cantor Maria ESVP, Investor Relations · SVP, Investor Communications
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008374 · doc1.xml · derivative · entry 1 Cantor Maria E · CIK 0001542768 · SVP, Investor Relations · SVP, Investor Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 22:04 UTC Amendment |
Firuta Paul EChief Commercial Officer
|
GrantPreformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008376 · doc1.xml · derivative · entry 2 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 22:04 UTC Amendment |
Firuta Paul EChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008376 · doc1.xml · derivative · entry 1 Firuta Paul E · CIK 0001602727 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Mar 3, 2017 16:25 UTC |
Kapusta Matthew CDirector · CEO, CFO, Managing Director
|
GrantPerformance Share Units · Derivative | 162,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010423 · doc1.xml · derivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,124 Underlying: Ordinary Shares · 162,500 shares Expires not disclosed F1 · derivative.exercise_date: Performance Shares Units of a maximum of 162,500 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F2 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.